The Texas Heart Institute
D

Antihyperglycemic Medications for CV Risk Reduction: a Cardiologist's Perspective

By The Texas Heart Institute FEATURING Darren K. Mcguire
By The Texas Heart Institute FEATURING Darren K. Mcguire
1,231 views
January 18, 2024
1 Comment
Login to view comments. Click here to Login

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Related Content

AUTOPLAY
64:45
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

Primer on Diabetes Management

Feat. S. Inzucchi
11:37
ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich
11:25
ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster
18:43
ASPC 2019 Congress on CVD Prevention

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

Feat. R. DeFronzo
15:06
Robert Busch

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

26:01
Cardiology Fiesta 2017

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Feat. R. DeFronzo
12:26
Juan Frias

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

27:14
MUSC Cardiology

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

Feat. R. Mentz
15:33
Ken Fujioka

Could GLP-1's be a 'Game Changer' For Weight Loss? Ca…

17:44
Rita Jermyn

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

27:24
Cardiometabolic Health Congress (CMHC)

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Feat. L. Sloan
13:07
Michelle Kittleson

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

09:52
AHA 2022 Conference Coverage

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

Feat. R. Mentz
20:24
Diana Isaacs

Tirzepatide for Type 2 Diabetes

26:49
Diana Isaacs

Tirzepatide Updates

35:16
Scripps Health

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Feat. M. Kittleson
06:31
Susan Brian

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

05:08
Susan Brian

The Differences Between the Products of GLP1's and GLP/GIPs

12:30
Houston Methodist Hospital

Amyloidosis Types and Pathophysiology

Feat. B. Trachtenberg
29:08
Scripps Health

Case Presentation: Complex PCI with IABP

Feat. R. Khedraki, T. Heywood, R. Mohan, A. Srivastava